Skip to main content

Table 2 Univariable Firth’s logistic regression analysis for baseline characteristics and type of progression: OR (95%CI)

From: Mode of progression after radioembolization in patients with colorectal cancer liver metastases

  PD GIHM (n = 20) GEHM (n = 37) NIHM (n = 35) NEHM (n = 57) GM (n = 45) NM (n = 63)
Age in years 1.02 (0.97; 1.07) 0.99 (0.02; 9.75) 1.01 (0.97; 1.06) 1.02 (0.98; 1.06) 1.00 (0.96; 1.05) 1.01 (0.97; 1.06) 1.01 (0.97; 1.05)
Chemotherapy* 0.88 (0.01; 88.46) 0.74 (0.26; 2.01) 0.87 (0.37; 2.05) 0.37 (0.14; 0.91) 0.63 (0.26; 1.51) 0.57 (0.24; 1.33) 0.48 (0.19; 1.19)
Type of microspheres**, Glass 1.11 (0.32; 4.53) 0.71 (0.18; 2.41) 2.53 (0.87; 7.56) 1.71 (0.59; 4.99) 1.5 (0.50; 4.89) 1.79 (0.62; 5.35) 1.94 (0.59–7.65)
Type of microspheres, holmium 0.67 (0.22; 2.14) 0.57 (0.14; 1.88) 1.75 (0.63; 4.86) 0.85 (0.29; 2.38) 0.90 (0.33; 2.50) 1.19 (0.44; 3.22) 0.81 (0.29–2.31)
Extrahepatic metastases at baseline 7.8 (2.37; 35.53) 2.39 (0.89; 6.84) NA 1.83 (0.79; 4.32) 3.06 (1.28; 7.72) NA 2.86 (1.14; 7.66)
Primary tumor in situ 1.90 (0.30; 37.11) 0.76 (0.08; 3.96) 1.12 (0.24; 4.88) 3.86 (0.87; 22.5) 2.73 (0.54; 27.1) 1.32 (0.30; 6.21) 2.00 (0.39; 19.9)
WHO status*** 0.87 (0.32; 2.46) 0.43 (0.10; 1.43) 0.91 (0.35; 2.33) 0.90 (0.33; 2.33) 0.50 (0.19; 1.31) 0.86 (0.34; 2.19) 0.81 (0.30; 2.27)
KRAS status§ 3.38 (0.75; 23.95) 1.88 (0.56; 6.45) 2.75 (0.90; 8.78) 4.78 (1.52; 16.5) 3.92 (1.11; 17.2) 2.85 (0.92; 9.48) 2.67 (0.74; 11.86)
Time since diagnosis of metastases§§ 1.06 (1.01; 1.11) 0.98 (0.94; 1.01) 1.01 (0.99; 1.04) 0.98 (0.95; 1.01) 1.02 (0.99; 1.05) 1.01 (0.98; 1.03) 1.02 (0.99; 1.07)
CEA level before treatment 1.00 (0.99–1.00) 1.00 (95%CI 0.99–1.00) 1.00 (95%CI 0.99–1.00) 1.00 (95%CI 0.99–1.00) 1.00 (0.99–1.00) 1.00 (0.99–1.01) 1.00 (0.99–1.01)
Primary tumor location 3.88 (1.00–25.75) 0.88 (0.26–2.63) 0.98 (0.35–2.63) 1.72 (0.65–4.59) 2.96 (0.98–11.11) 0.94 (0.36–2.49) 3.88 (1.00–25.76)
Tumor load, 25–50% 1.63 (0.50–6.35) 0.56 (0.14–1.79) 1.17 (0.42–3.16) 0.58 (0.20–1.59) 0.94 (0.34–2.72) 1.04 (0.39–2.74) 1.11 (0.36–3.90), 0.7
Tumor load, > 50% 0.73 (0.20–3.10) 1.24 (0.30–4.49) 1.67 (0.47–5.76) 1.64 (0.48–5.76) 0.55 (0.16–1.95) 1.66 (0.49–6.12) 0.66 (0.18–2.77)
  1. This table shows the associations (odds ratio and 95%CI) between baseline characteristics and modes of progression as described by RECIST at 3 months post-treatment
  2. Abbreviations: GIHM growth of intrahepatic metastases, GEHM growth of extrahepatic metastases, NIHM new intrahepatic metastases, NEHM new extrahepatic metastases, GM growth of metastases (GEHM + GIHM), NM new metastases (NEHM + NIHM), NA not applicable, RE radioembolization, OR odds ratio, PD progressive disease, 95% CI 95% confidence interval
  3. *Previous treatment with 1st- versus 2nd-line chemotherapy
  4. **Yttrium-90 resin (reference) versus yttrium-90 glass and holmium-166
  5. ***WHO performance status 0 versus 1, 2
  6. §KRAS mutation versus KRAS wild type
  7. §§Right-sided primary tumors versus left-sided primary tumors
  8. < 25% liver involvement versus 25–50% and > 50% liver involvement